On July 11, 2025, the scientific community was stunned by a revolutionary breakthrough in bioinformatics and artificial intelligence — researchers revealed that AI can now design new proteins in seconds, unlike the months or years required by traditional methods. This discovery could reshape pharmacology, biotechnology, and molecular medicine. A research team from the University of Cambridge, in collaboration with DeepMind and the Francis Institute in Vienna, developed an AI system capable of instantly generating molecular structures of proteins with specific functions — such as binding to pathogens or breaking down compounds. The technology is based on transformer architecture with 3D training, allowing AI not just to predict protein structures like AlphaFold, but to design them from scratch based on biological objectives. Protein design is a key task in drug development. Traditional approaches involve complex modeling and lengthy experiments. AI modeling shortens this timeline from years to days; it enables the design of functional proteins, like enzymes that break down microplastics; it accelerates vaccine and antibody development; and it reduces costs. Applications include oncology, antibiotic resistance, neurodegenerative diseases, and ecology. Despite its promise, experts warn of ethical risks: fast protein generation could lead to bioweapons or mutations. Therefore, international regulatory norms are urged.